Hanmi Pharma Signs $1.26B Licensing Deal with Eli Lilly for Gut Repair Drug Sonefpeglutide

The Quick Take

• Hanmi Pharmaceutical signed a licensing deal with Eli Lilly for its biotech drug candidate Sonefpeglutide (HM15912) worth up to $1.26 billion.
• The deal includes a non-refundable upfront payment of $75 million, with the remainder in development and commercial milestone payments.
• Sonefpeglutide targets gut mucosal growth and repair, representing a distinct therapeutic mechanism from existing GLP-1 weight loss drugs.

Hanmi Pharmaceutical announced a major out-licensing agreement with Eli Lilly, granting the US pharmaceutical giant rights to develop, manufacture, and commercialize Sonefpeglutide (HM15912), a biotech drug candidate targeting gut mucosal repair and growth. The total deal value reaches up to $1.26 billion (approximately 1.9 trillion Korean won) including milestone payments, with a guaranteed non-refundable upfront of $75 million that represents real, risk-adjusted value to Hanmi. The partnership positions Eli Lilly, already the dominant global GLP-1 franchise holder through its Tirzepatide (Zepbound/Mounjaro) and Semaglutide competitor products, to potentially expand its gastrointestinal therapy portfolio with a mechanistically distinct asset.

The licensing deal has significant implications for Hanmi Pharmaceutical's valuation and Korea's biotechnology sector positioning. A $75 million upfront from Eli Lilly — one of the world's most selective pharmaceutical deal-makers — is powerful third-party validation of HM15912's clinical promise. Korean biotech investors will re-rate Hanmi's pipeline based on this deal signal, with peer companies like OliX Pharmaceuticals and Boryung potentially benefiting from improved sector sentiment. Eli Lilly gains access to a gut repair mechanism that could complement its existing metabolic disease portfolio if HM15912 advances through clinical trials, creating a synergistic relationship between their core GLP-1 franchise and this novel asset.

The critical forward signals are Hanmi's disclosure of clinical trial timelines for Sonefpeglutide under Eli Lilly's development plan, and any interim data readouts that would trigger the milestone payment schedule. Regulatory progress in Phase 2/3 trials is the key value-creation pathway. The macro variable governing this thesis is the GLP-1 and metabolic disease investment cycle: if Eli Lilly's existing franchises continue generating exceptional returns, the company has both the capital and strategic rationale to advance Sonefpeglutide aggressively — but if the GLP-1 competitive landscape shifts unfavorably (competitor drug entries, pricing pressure), Eli Lilly may slow development timelines, affecting Hanmi's milestone receipt schedule.

Synthesized from 2 sources.